8-K: Phathom Pharmaceuticals Reports Strong Q3 2024 Revenue Growth Driven by VOQUEZNA Launch

Phathom Pharmaceuticals announced a significant increase in revenue and prescriptions for its GERD treatment, VOQUEZNA, in the third quarter of 2024, alongside expanded commercial access.

Summary

• Phathom Pharmaceuticals reported a substantial increase in net revenues to $16.4 million in Q3 2024, compared to $7.3 million in Q2 2024, representing a 120% sequential quarterly increase.
• The company saw a 138% increase in total prescriptions filled for VOQUEZNA products since the last quarterly report, reaching over 143,000 prescriptions filled to date.
• Commercial access for VOQUEZNA tablets has expanded to cover over 80% of U.S. commercial lives, with an estimated 120 million covered lives.
• The company's net loss for Q3 2024 was $85.6 million, compared to $43.2 million in Q3 2023, which includes a non-cash stock-based compensation charge of $5.6 million.
• Non-GAAP adjusted net loss for Q3 2024 was $67.9 million, compared to $30.8 million for the same period in 2023.
• Research and development expenses decreased to $8.7 million in Q3 2024, down from $12.3 million in Q3 2023, due to the wrap-up of a clinical trial.
• Selling, general, and administrative expenses increased to $76.1 million in Q3 2024, up from $23.4 million in Q3 2023, due to commercial infrastructure buildout and marketing activities.
• As of September 30, 2024, the company had $334.7 million in cash and cash equivalents, with up to an additional $125 million available under its term loan.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, prescription increases, and expanded market access for VOQUEZNA. While there are significant losses, they are expected during the commercialization phase, and the company's financial position appears stable with the recent capital raise.

Positives

• VOQUEZNA's commercial launch is showing strong momentum with significant increases in revenue and prescriptions.
• The expansion of commercial access to over 80% of U.S. commercial lives indicates strong market penetration.
• The increase in the prescriber base demonstrates growing acceptance of VOQUEZNA among healthcare providers.
• The successful $130 million equity raise strengthens the company's financial position.
• Positive data from studies presented at the ACG 2024 Annual Meeting highlight the potential of VOQUEZNA for both daily and as-needed use.
• The company believes its current cash resources will be sufficient to achieve cash flow positivity.

Negatives

• The company reported a net loss of $85.6 million for Q3 2024, which is significantly higher than the $43.2 million loss in Q3 2023.
• Selling, general, and administrative expenses have increased substantially due to commercialization efforts.
• Non-GAAP adjusted net loss also increased to $67.9 million in Q3 2024, compared to $30.8 million in Q3 2023.

Risks

• The company's ability to successfully commercialize VOQUEZNA depends on factors such as coverage and reimbursement levels and market acceptance.
• The company may use its capital resources sooner than expected, potentially requiring them to reduce expenses or raise additional capital.
• There are inherent risks in the clinical development of vonoprazan, including unexpected adverse side effects or inadequate efficacy.
• The company's estimates regarding patient population and commercial coverage could prove to be inaccurate.
• The company is dependent on third parties for product manufacturing, research, and testing.

Future Outlook

The company believes its current cash resources, operating plan, estimated product revenues, and potential funds available under its existing term loan will be sufficient to fund operations and enable Phathom to achieve cash flow positivity. They also plan to initiate a Phase 2 program for Eosinophilic Esophagitis (EoE) in the first half of 2025.

Management Comments

• Terrie Curran, President and CEO of Phathom, stated that they are thrilled with Phathom's progress over the past quarter, particularly the strong and continued momentum of the commercial launch for VOQUEZNA.
• Management believes they remain well-positioned to deliver on VOQUEZNA's blockbuster opportunity.

Industry Context

The announcement highlights the competitive landscape in the gastrointestinal disease treatment market, where Phathom is positioning VOQUEZNA as a potential replacement for standard proton pump inhibitors (PPIs). The expansion into Non-Erosive GERD and the exploration of as-needed dosing are key strategies to capture a larger market share.

Comparison to Industry Standards

• Phathom's 120% sequential quarterly revenue growth is a strong indicator of successful product launch compared to typical pharmaceutical product launches.
• The 138% increase in prescriptions filled since the last quarterly report suggests a rapid adoption rate, which is a positive sign compared to other new drug launches in the same therapeutic area.
• The expansion of commercial access to over 80% of U.S. commercial lives is a significant achievement, indicating a strong payer coverage compared to other similar products.
• While the net loss is substantial, it is not uncommon for companies in the commercialization phase of a new drug to incur significant expenses, especially in sales and marketing. The increase in SG&A expenses is in line with the commercialization efforts of other pharmaceutical companies.
• The company's cash position of $334.7 million, with an additional $125 million available under a term loan, provides a solid financial base compared to other companies in the same stage of development.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and prescription numbers positively, but will also be aware of the significant net loss.
• Employees may be encouraged by the company's progress and growth, but also aware of the increased expenses.
• Customers (patients) will benefit from increased access to VOQUEZNA, a new treatment option for GERD.
• Suppliers may see increased demand for their products and services due to the commercial launch.
• Creditors will be monitoring the company's financial performance and cash flow.

Next Steps

• Phathom plans to initiate a Phase 2 program for Eosinophilic Esophagitis (EoE) in the first half of 2025.
• The company will continue to review real-world data to assess the value and potential timing for advancing a separate Phase 3 program to validate the As Needed dosing of VOQUEZNA for active heartburn episodes.

Key Dates

Keywords

VOQUEZNA, Phathom Pharmaceuticals, GERD, Gastrointestinal Diseases, Vonoprazan, Prescriptions, Revenue, Commercial Launch, Eosinophilic Esophagitis, Non-Erosive GERD